Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311493 | 0.88 | OPRM1 (0.45) | OPRM1OPRL1BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3406175 | 0.83 | BDKRB1 (0.41) | OPRM1OPRL1BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3310795 | 0.81 | OPRM1 (0.40) | OPRM1OPRL1BDKRB1RAB9ANPC1 | |
| SCHEMBL3314516 | 0.79 | BDKRB1 (0.36) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3408684 | 0.79 | BDKRB1 (0.40) | OPRM1OPRL1BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3408728 | 0.78 | BDKRB1 (0.40) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL12694641 | 0.78 | OPRM1 (0.40) | OPRM1OPRL1RAB9A | |
| SCHEMBL5121357 | 0.77 | HCRTR1 (0.39) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL3407195 | 0.77 | HCRTR1 (0.39) | BDKRB1HCRTR1HCRTR2 | |
| SCHEMBL5128054 | 0.76 | HCRTR1 (0.39) | BDKRB1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | claimed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | OPRM1 82/4885OPRL1 12/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.